Kornimate/medical-research-clean huggingface dataset:
the use of an external ultrasound fixator (probefixr) on intensive care patients

Conditions: Hypovolemia

Summary: study to assess the feasibility of an external ultrasound fixator (probefix)

rationale: study to assess the feasibility of an external ultrasound fixator (probefix) objective: cardiac output measurements using transthoracic ultrasound (tte) with and without the use of the probefixr will be evaluated in terms of accuracy. the tte measurements will be combined with another form of cardiac output measurements (flotracr) after a passive leg rasing (plr) test. study design prospective, feasibility study study population: adult intensive care patients ( \> 18 years) intervention (if applicable): consecutive adult patients on the icu in which the flotracr monitor is used will be evaluated after detection of hypovolemia. main study parameters/endpoints: * percentage of patients in which the probefixr can be used * the correlation between the measurements done by flotracr and tte with and tte without probefixr although no side effects are to be expected the investigators will monitor the patients after the probefix is removed for any skin damage. the investigators will grade this damage into 3 categories: * no skin marks * mild skin marks (no treatment necessary) * severe skin marks (surgical or medical treatment necessary) * if the patients are awake the investigators will ask them whether they felt the probefixr to be unpleasant on a scale of 0-10 (0 being: i did not feel anything and 10 being very unpleasant).

Eligibility criteria:
inclusion criteria: * adult intensive care patients ( \> 18 years), with hypovolemia detected with flotrac (svv \> 10%) exclusion criteria: * pregnancy * atrial fibrillation or other irregular heart rhythm * pulmonary edema * plr not possible (eg neurological disease, spinal trauma, restricted limb movement, deep venous thrombosis, or any other reason as indicated by the attending intensivist). * age \< 18 years

Keywords: ultrasound cardiac output probefix passive leg raising test
"study of the effects of serum and follicular fluid relaxin levels on ovarian function in ivf cycles"

Conditions: Infertility; Reproductive Techniques, Assisted; Oocyte Maturation

Summary: the study evaluated the effect of serum relaxin and follicular fluid levels on the number and quality of oocytes, fertilization, the number and quality of the embryos in ivf protocols.

relaxin is one of the promising indicators of oocyte quality and prognosis of the effectiveness of invitro fertilization protocols. the hormone plays an important role in the processes of folliculogenesis, growth and maturation of oocytes, development of embryos, implantation processes, pregnancy and childbirth. a pilot study was conducted on a group of patients undergoing infertility treatment using assisted reproductive technologies in the superovulation stimulation protocol using gonadotropin releasing hormone antagonists. blood and follicular fluid samples were obtained on the day of transvaginal follicular puncture. the results allow us to consider the hormone relaxin as a promising predictor of the result of ovarian stimulation, the effectiveness of fertilization in ivf cycles.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of primary or secondary infertility 2. must be signed the voluntary informed consent to participate in the study. exclusion criteria: 1. the presence of ivf contra-indications. 2. clinical diagnosis of large uterine fibroids. 3. bmi\> 35 kg / m2 4. morphological diagnosis of endometrial hyperplastic processes 5. clinical diagnosis of infectious. 6. clinical diagnosis of systemic autoimmune diseases. 7. insulin dependent diabetes 8. oncological diseases

Keywords: infertility relaxin oocytes embryo quality ivf
pancreatic neuroendocrine tumor：factor of surgery influencing survival

Conditions: Pancreatic Neuroendocrine Tumor

Summary: investigator determined the factor of surgery associated with the survival of pancreatic neuroendocrine tumor.

the variables including clinical characteristics, surgical data and pathological findings are examined by univariate and multivariate analyses.

Eligibility criteria:
inclusion criteria: * the patients with pancreatic neuroendocrine tumor underwent pancreatectomy exclusion criteria: * the patients with pancreatic neuroendocrine tumor did not undergo pancreatectomy
portosinusoidal vascular diseases and systemic sclerosis

Conditions: PSVD With or Without SSc

Summary: porto-sinusoidal vascular disorders (psvd) is a heterogeneous clinico-pathological entity characterized by alterations in small liver vessels. "nodular regenerative hyperplasia (nrh)" is the most common psvd. the most frequent liver disease associated with systemic sclerosis (ssc) is primary biliary cholangitis reported in 2 to 22% of cases. nrh prevalence estimated to 1.4%, may be underestimated as nrh diagnosis is histologic and usually suspected in case of complications due to portal hypertension. few data are available about nrh associated with ssc resulting in a lack of knowledge of the characteristics and outcome of these patients.

the study aims to compare the outcome of patients with mvps associated with ssc to patients with mvps without ssc. this work is a multicenter retrospective study comparing two groups of adult patients, one with mvps associated with ssc and the other with mvps without ssc. patients with mvps associated with ssc will be recruited from french university hospital departments of hepatogastroenterology and internal medecine. patients with mvps without ssc will be recruited from the beaujon hospital database dedicated to liver vascular diseases.

Eligibility criteria:
inclusion criteria: * psvd (valdig criteria) * ssc (acr/eular 2013 criteria) exclusion criteria: * liver cirrhosis * limited scleroderma * autoimmune hepatitis * primary biliary cholangitis

Keywords: porto-sinusoidal vascular disease nodular regenerative hyperplasia systemic sclerosis
fruquintinib after icis treatment in unresectable hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Immune Checkpoint Inhibitors; Anti-angiogenic Therapy; Second-line Treatment

Summary: nowadays, there are few second-line treatment options for advanced hepatocellular carcinoma (hcc). in order to further improve the efficacy of second-line treatment for advanced hcc, we plan to conduct a phase ii clinical study to explore the efficacy and safety of the new second-line treatment for advanced hcc. as a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor -1/2/3 (vegfr 1/2/3), fruquintinib had demonstrated a strong antitumor efficacy in colorectal cancer patients who had previously received standard chemotherapy. compared with placebo, fuquinitinib significantly extended overall survival in patients with metastatic colorectal cancer (median os, 9.3 months vs 6.6 months; hr, 0.65; p\<0.001) and progression-free survival (median pfs, 3.7 months vs 1.8 months; hr, 0.26; p\<0.001). additionally, a phase ii clinical study had showed that sintilimab combined with fruquintinib was with a promising anti-tumor activity in patients with advanced hcc who had received standard treatment, with a median pfs of 7.4 months and a tumor response rate of 31.6%. therefore, we intend to conduct this clinical study to explore the efficacy and safety of fruquintinib as second-line treatment for patients with unresectable hcc previously treated with immune checkpoint inhibitors.


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older * with unresectable, locally advanced, or metastatic hcc, with the diagnosis confirmed by histologic or cytologic analysis or clinical features according to the american association for the study of liver disease criteria * who had previously received immune checkpoint inhibitors * had at least on measurable disease, as defined by response evaluation criteria in solid tumours version 1.1 (recist v1.1) criteria * had a baseline eastern cooperative oncology group (ecog) performance status of 0 or 1 * had a child-pugh liver function score of 7 or less * had adequate hematologic and organ function (absolute neutrophil count ≥1.2×109/l, platelet count ≥60×109/l, total bilirubin \< 30μmol/l, albumin ≥ 30g/l, aspartate transaminase and alanine transaminase ≤ 5×upper limit of the normal, creatinine clearance rate of ≤ 1.5×upper limit of the normal, and left ventricular ejection ≥ 45%) exclusion criteria: * history of hiv, organ allograft * combined with other malignant tumors * evidence of hepatic decompensation, bleeding diathesis or event * allergy to the investigational agents or any agent given in association with this trial * incomplete medical information.
erythropoietin in premature infants to prevent encephalopathy

Conditions: Premature Infant

Summary: the main goal of this trial is to investigate whether early administration of human erythropoietin (epo) in preterm infants improves neurodevelopmental outcome at 18 months corrected age. this study is designed as randomized, double-masked, placebo controlled multicenter study involving at least 312 patients.

epo has been safely used for prevent preterm anemia and recent studies have shown the neuro-protective effect. our hypothesis is that epo could prevent preterm brain injury and reduce the rate of premature death and disability from encephalopathy. the aims of this study include: to investigate the safety and efficacy of epo by using 1000u/kg higher than the dose of anemia treatment (250u/kg); to evaluate the effect of epo on neurodevelopment in preterm infants; to detect biological and imaging indicators of epo. eligible premature infants will be enrolled in this double-blind, placebo-controlled randomized trial from the neonatal neurological intensive care unit (nnicu) at 7 children's hospital in 6 provinces of china. subjects will be enrolled within the first 24 hours of life and randomly assigned to receive epo or saline vehicle placebo. standard nicu care will be provided to all subjects. pharmacokinetic data, serial brain electrophysiologic and imaging exams, circulating inflammatory mediators, biomarkers and complications like polycythemia, neutropenia, thrombocytopenia, hypertension, sepsis, hemorrhage, seizure, necrotizing enterocolitis (nec), persistent ductus arterious (pda), apnea of prematurity, pulmonary haemorrhage, pulmonary hypertension, prolonged blood coagulation time, retinopathy of prematurity (rop), cardiac arrhythmia, major venous thrombosis, renal failure treated with dialysis, pneumonia, pulmonary airleak and chronic lung disease will be collected at established time points during the study period. at 18 months corrected age, subjects will undergo a neurodevelopmental evaluation assessing for cerebral palsy, bayley scores of mental development index (mdi) use.

Eligibility criteria:
inclusion criteria: 1. birthweight less or equal 1500 grams 2. less than 32 weeks gestation at birth 3. less than 48 hours of life at time of enrollment 4. written informed consent of parent or guardian exclusion criteria: 1. intrauterine growth retardation 2. severe congenital anomalies adversely affecting life expectancy or neurodevelopment 3. genetic metabolic diseases 4. seizures within first 24 hours of life 5. severe neutropenia (anc \< 500 cells/microl) within first 24 hours of life 6. polycythemia (hct \> 65%) within first 24 hours of life 7. thrombocytopenia (platelets \< 50k cells/microl) within first 24 hours of life 8. hypertension (sbp \> 100mmhg) without vasopressor support within first 24 hours of life 9. microcephaly 10. grade iii-iv intracranial hemorrhage termination 1. required by parent or guardian; 2. polycythemia through blood transfusion can not be relieved 3. oliguria（\<0.5ml/kg/h for at least 24 hours） 4. progression of azotemia 5. pulmonary hypertension or cardiac arrhythmia
endoscopic ultrasound (eus) features of chronic pancreatitis

Conditions: Chronic Pancreatitis

Summary: the purpose of this study is to correlate endoscopic ultrasound (eus) criteria for chronic pancreatitis with surgical pathology.


Eligibility criteria:
patients who are eligible are individuals who have: * normal pancreas * suspected chronic pancreatitis * established chronic pancreatitis (by ercp, mri, previous eus, ct) * pancreatic cancer patients who are not eligible are individuals who have: • an uncorrectable coagulopathy (platelet \ 1.5), or bleeding disorder, or are unable to discontinue anticoagulation 5-7 days prior to eus (aspirin and bridging therapy with lovenox are allowed, clopidogrel is not allowed)

Keywords: chronic pancreatitis
phase ii trial of chop-r followed by zevalin and rituxan in follicular lymphoma

Conditions: Non-Hodgkin Lymphoma

Summary: the purpose of this study is to determine the complete response rate when chop-r chemotherapy in followed by zevalin in previous untreated patients with follicular lymphoma

patients with follicular lymphoma who require therapy and have been previously untreated are eligible for this non-randomized, phase ii study evaluating up front therapy with chop-r x 3 cycles followed by zevalin and 4 additional weeks of rituxan.the complete response will be determined by combining iwc criteria and pet scanning.secondary objectives include pet-ct conversion rate, frequency and severity of adverse events, duration of complete remission and time to next lymphoma therapy.

Eligibility criteria:
inclusion criteria: * conformed diagnosis of follicular lymphoma, grades 1,2 or 3 * no prior chemotherapy * no prior monoclonal antibody therapy * bulky or symptomatic disease, stage ii-iv * performance status 0-2 exclusion criteria: * impaired bone marrow reserve * presence of cns lymphoma * serious nonmalignant disease or active infection

Keywords: non-hodgkin lymphoma
safety and efficacy study of kai-9803 to treat subjects with st elevation myocardial infarction [heart attack]

Conditions: Myocardial Infarction; Cardiovascular Diseases; Pathologic Processes

Summary: the purpose of this study is to determine whether kai-9803 is safe and effective in reducing infarct size in subjects with st elevation myocardial infarction (heart attack) undergoing a percutaneous coronary intervention (pci). a select number of sites will also participate in a substudy where eligible patients will undergo an additional procedure;cardiac magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: * acute stemi and has a planned emergent primary pci procedure * continuous symptoms of cardiac ischemia and present to the primary pci facility within 6 hours of symptom onset exclusion criteria: * persistent systolic blood pressure \< 90 mm hg

Keywords: heart diseases myocardial ischemia infarction myocardial infarction
phase 1/2 clinical trial of pr001 in infants with type 2 gaucher disease (provide)

Conditions: Gaucher Disease, Type 2

Summary: j3z-mc-ojab is an open-label, phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose ly3884961 (formerly pr001) in infants diagnosed with type 2 gaucher disease (gd2). for each patient, the study will be approximately 5 years in duration. during the first 12 months after dosing, patients will be evaluated for the effects of ly3884961 on safety, tolerability, immunogenicity, biomarkers, and efficacy. patients will be followed up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.


Eligibility criteria:
inclusion criteria: * bi-allelic gba1 mutations consistent with a diagnosis of gd2 confirmed by the central laboratory. * clinical diagnosis of gd2 * parent/legal guardian is capable of providing signed informed consent; including compliance with the requirements and restrictions listed in the informed consent form (icf) in this protocol. * patient has a parent/legal guardian able to participate in the study as a source of information on the patient's health status and cognitive and functional abilities (including providing input into the rating scales). exclusion criteria: * significant cns disease other than gd2 that may be a cause for the patient's symptoms or interfere with study objectives. * achieved independent gait. * severe peripheral symptoms of gd which, in the opinion of the investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study. * concomitant disease, condition, or treatment which, in the opinion of the investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study. * use of any substrate reduction therapy (srt) for gd treatment. * use of prohibited medications, herbals, or over-the-counter agents as listed in the protocol. * any type of prior gene or cell therapy. * use of systemic immunosuppressant or corticosteroid therapy other than protocol-specified immunosuppression. * participation in another investigational drug or device study within the past 3 months. * brain mri (magnetic resonance imaging) and mra (magnetic resonance angiography) showing clinically significant abnormality deemed a contraindication to intracisternal injection. * clinically significant laboratory test result abnormalities assessed at screening. * contraindications or intolerance to radiographic visualization methods (e.g. mri, mra, ct), and intolerance to contrast agents used for mri or ct scans. * contraindications to general anesthesia or sedation. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: gaucher disease gd gaucher type 2 gaucher neuronopathic gaucher ngd aav9 gba gene therapy glucocerebrosidase gba1 mutation infants
predicting volume response study

Conditions: Shock; Hypovolemia

Summary: the purpose of this study is to understand and document measurements in heart stroke volume (the volume or amount of blood pumped per heart beat) and cardiac output (the volume or amount of blood pumped by your heart per minute) during a passive leg raise maneuver (elevation of the legs), and to determine if these measurements can predict changes in the same as a result of fluid or blood product administration.

the administration of intravenous fluid and blood products for treatment of hypovolemia is common in the icu setting. static resuscitation endpoints such as heart rate, blood pressure, and cvp are frequently used to guide this therapy, despite compelling evidence they are unreliable in predicting patient response to therapeutic volume administration or as an endpoint for ongoing therapy. dynamic parameters such as continuous stroke volume and cardiac output (index) monitoring, along with pulse pressure and stroke volume variance measures are more reliable in predicting and measuring response to fluid challenge and therapeutic volume administration. the purpose of this study is to observe changes in stroke volume (sv) and cardiac output (co) during a passive leg raise maneuver (plr) as a surrogate to volume challenge, and to determine if these changes can predict changes in the same parameters with fluid or blood product administration in surgical patients. the plr maneuver involves positioning the patient to the supine position and elevating the legs to 45 degrees. the plr moves blood from the capacitance vessels of the legs to the heart, potentially improving stroke volume (sv) and cardiac output (co), without the administration of intravenous fluids. plr may predict whether sv or co would improve with administration of fluids, and guide decisions on whether fluid administration would be beneficial. stroke volume and cardiac output (index) will be calculated by a commercial pulse power arterial pressure cardiac output system (lidcorapid), using the patients' measured heart rate and blood pressure imported from the bedside monitor. by using the combination of a reversible volume challenge (plr) and a minimally invasive monitoring system, it is hoped that a more reliable method will emerge to both predict a response and guide therapeutic volume administration, while reducing the risk associated with fluid volume overload.

Eligibility criteria:
inclusion criteria: * patients 18 years or older admitted to the surgical intensive care unit, anticipated to receive iv fluid boluses or blood products, with the presence of an arterial pressure line. exclusion criteria: * patients under 18 years of age, * pregnancy, * prisoners, * inability to lay in the supine position, * conditions of the lower extremities, * pelvis or spine that preclude elevation of the legs

Keywords: stroke volume cardiac output pulse pressure variance stroke volume variance passive leg raise fluid challenge central venous pressure
"comparison of spirulina gels for treating stage ii grade b periodontitis"

Conditions: Periodontitis Stage II

Summary: this randomized controlled clinical study investigates the effectiveness of spirulina gel and spirulina nanoparticles gel in treating stage ii grade b periodontitis. the research aims to compare the two formulations in terms of clinical, radiological, and biochemical outcomes, such as pocket depth reduction, alveolar bone density improvement, and inflammatory marker levels. the study seeks to provide insights into the potential of spirulina-based therapies for enhancing periodontal health.


Eligibility criteria:
inclusion criteria: * patients with good systemic health. * patients who can maintain good oral hygiene. * attachment loss 3-4 mm and probing pocket depth ≤ 5mm. exclusion criteria for this study include: · * any systemic disease that affects the periodontium. · * pregnant, postmenopausal women. · * people who take anti-inflammatory drugs, antibiotics, or vitamins within the previous 3 month. * people who use mouth washes regularly · * participation in other clinical trials.